These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28314412)

  • 41. Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease.
    Koshibu K; van Asperen J; Gerets H; Garcia-Ladona J; Lorthioir O; Courade JP
    Pharmacology; 2015; 96(5-6):240-7. PubMed ID: 26382237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.
    Ramsden N; Perrin J; Ren Z; Lee BD; Zinn N; Dawson VL; Tam D; Bova M; Lang M; Drewes G; Bantscheff M; Bard F; Dawson TM; Hopf C
    ACS Chem Biol; 2011 Oct; 6(10):1021-8. PubMed ID: 21812418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LRRK2 Ablation Attenuates Αlpha-Synuclein-Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo.
    Van der Perren A; Cabezudo D; Gelders G; Peralta Ramos JM; Van den Haute C; Baekelandt V; Lobbestael E
    Neurotherapeutics; 2021 Apr; 18(2):949-961. PubMed ID: 33594532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Kinases as targets for Parkinson's disease: from genetics to therapy.
    Vancraenenbroeck R; Lobbestael E; Maeyer MD; Baekelandt V; Taymans JM
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):724-40. PubMed ID: 21838679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and Preliminary Evaluation of [
    Chen Z; Shao T; Gao W; Fu H; Collier TL; Rong J; Deng X; Yu Q; Zhang X; Davenport AT; Daunais JB; Wey HY; Shao Y; Josephson L; Qiu WW; Liang S
    ChemMedChem; 2019 Sep; 14(17):1580-1585. PubMed ID: 31365783
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors.
    Weng JH; Ma W; Wu J; Sharma PK; Silletti S; McCammon JA; Taylor S
    ACS Chem Biol; 2023 Apr; 18(4):810-821. PubMed ID: 37043829
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents.
    Salado IG; Zaldivar-Diez J; Sebastián-Pérez V; Li L; Geiger L; González S; Campillo NE; Gil C; Morales AV; Perez DI; Martinez A
    Eur J Med Chem; 2017 Sep; 138():328-342. PubMed ID: 28688273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
    West AB
    Exp Neurol; 2017 Dec; 298(Pt B):236-245. PubMed ID: 28764903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease.
    Wojewska DN; Kortholt A
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures.
    Sanz Murillo M; Villagran Suarez A; Dederer V; Chatterjee D; Alegrio Louro J; Knapp S; Mathea S; Leschziner AE
    Sci Adv; 2023 Dec; 9(48):eadk6191. PubMed ID: 38039358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors.
    Ding X; Stasi LP; Ho MH; Zhao B; Wang H; Long K; Xu Q; Sang Y; Sun C; Hu H; Yu H; Wan Z; Wang L; Edge C; Liu Q; Li Y; Dong K; Guan X; Tattersall FD; Reith AD; Ren F
    Bioorg Med Chem Lett; 2018 May; 28(9):1615-1620. PubMed ID: 29588215
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate.
    Zaldivar-Diez J; Li L; Garcia AM; Zhao WN; Medina-Menendez C; Haggarty SJ; Gil C; Morales AV; Martinez A
    J Med Chem; 2020 Mar; 63(5):2638-2655. PubMed ID: 31825616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.